{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psychosis-schizophrenia/prescribing-information/monitoring/","result":{"pageContext":{"chapter":{"id":"ed339043-f5e2-5209-9ba0-cb06890e1050","slug":"monitoring","fullItemName":"Monitoring","depth":2,"htmlHeader":"<!-- begin field a895ee6a-1b98-45bb-9d4e-ab4c00900c6a --><h2>What monitoring is required?</h2><!-- end field a895ee6a-1b98-45bb-9d4e-ab4c00900c6a -->","summary":"","htmlStringContent":"<!-- begin item 3f697185-e990-4aed-b251-ab4c00900aea --><!-- begin field dfd3cf43-3dcb-4cce-a115-ab4c00900c6a --><ul><li><strong>When antipsychotics are initiated, baseline measurements should be taken in secondary care. People with a psychotic disorder will remain under the responsibility of the secondary care team for the first 12 months, or until their condition has stabilized (whichever is longer).</strong></li><li><strong>Regular monitoring may subsequently be done in primary care on specialist advice or depending on the person's care plan. </strong>This may include:<ul><li>Bodyweight, or body mass index (BMI) — weekly for the first 6 weeks, then at 3 months. Thereafter every 12 months, or more often if the person is gaining weight rapidly.</li><li>Serum electrolytes and urea including creatinine and estimated glomerular filtration rate — every 12 months.</li><li>Full blood count — every 12 months.</li><li>Blood lipids — 3 months after starting treatment, then every 12 months.</li><li>Plasma glucose or HbA1c — 3 months after starting treatment, then every 12 months. Additionally for clozapine and olanzapine repeat after the first month of treatment. Ask about symptoms of hyperglycaemia (such as polydipsia, polyuria, and increased appetite).</li><li>Pulse and blood pressure — during dose titration and at each dose change.<ul><li>Not required for amisulpride, aripiprazole, trifluoperazine, and sulpiride.</li></ul></li><li>Electrocardiography (ECG) — after dose changes. Ideally, also annually.<ul><li>Mandatory for haloperidol, pimozide, and sertindole; not required for antipsychotics with no effect, or a low-to-moderate effect on the QT interval and where there are no other risk factors for arrhythmia.</li></ul></li><li>Prolactin — 6 months after starting treatment, then every 12 months. Also ask about symptoms of raised prolactin (these include low libido, sexual dysfunction, menstrual abnormalities, gynaecomastia, and galactorrhoea).<ul><li>Not required for aripiprazole, clozapine, quetiapine, or olanzapine (less than 20 mg daily).</li></ul></li><li>Liver function tests – every 12 months.</li><li>Creatinine kinase if <a class=\"topic-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/prescribing-information/adverse-effects/\">neuroleptic malignant syndrome</a> is suspected.</li></ul></li><li><strong>Tests which need to be done every 12 months may be carried out at the annual physical review.</strong></li><li><strong>Clozapine</strong><ul><li>People taking clozapine are managed exclusively in secondary care. Clozapine can cause neutropenia or agranulocytosis, and frequent monitoring of the full blood count is required. This is carried out by the clozapine monitoring service.</li><li>Note: following fatal cases involving toxicity of clozapine and other antipsychotic medicines, the MHRA advises that monitoring blood concentration of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and sulpiride may be helpful in certain circumstances, such as patients presenting symptoms suggestive of toxicity, or when concomitant medicines may interact to increase blood concentration of these medicines.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field dfd3cf43-3dcb-4cce-a115-ab4c00900c6a --><!-- end item 3f697185-e990-4aed-b251-ab4c00900aea -->","topic":{"id":"9b90da89-2ffd-5b6a-9fc6-ea342404d5d8","topicId":"fd02ebc3-0f02-42b5-8737-e0608ca4330d","topicName":"Psychosis and schizophrenia","slug":"psychosis-schizophrenia","lastRevised":"Last revised in November 2020","chapters":[{"id":"d60310a0-752b-5399-8488-a567bf6a3925","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"10869ad6-510d-54db-bc6a-ce3618a1c478","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1025e31f-c89d-5344-b4ae-d5e8950a5c0e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"594160f5-1a9b-56f0-952c-5c400ea28785","slug":"changes","fullItemName":"Changes"},{"id":"e20c0ce8-30f6-5e09-81d1-3e6005f85efe","slug":"update","fullItemName":"Update"}]},{"id":"4c4f0990-85fa-5fc4-9a58-9f02a868a971","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"02637a5f-4552-5e73-9245-cf480497e9a5","slug":"goals","fullItemName":"Goals"},{"id":"8c88de52-9655-52d8-b302-67641ae05beb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c6754da2-fd29-5d45-8097-40b8ec0589cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"31a210b8-403b-5530-b1ea-0b44a2595f07","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5630117-b04c-558a-b516-41c3eab9adbd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e9e078fd-a616-51bf-944f-2efbb2a01feb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"99d1cff5-adca-5573-9fa8-58c2e9f937e0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"23ac3781-557a-57b8-95b5-83db37a53fda","slug":"definition","fullItemName":"Definition"},{"id":"3e7238cc-23d8-56f6-a8af-255ed6a876d7","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"9576e7c9-3a1e-57d3-bb86-a4e5e10462e1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b79b29b0-d7ad-5bad-87fd-e5a48ced5427","slug":"course-prognosis","fullItemName":"Course and prognosis"},{"id":"598444d7-6337-5133-a088-176b1f83ab01","slug":"complications","fullItemName":"Complications"}]},{"id":"a913b80f-eec4-5c47-9d9c-0b20f4648b73","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7897095-2be8-5df7-a7e3-c1060d4a453a","slug":"identifying-someone-at-risk-of-a-psychotic-disorder-or-experiencing-their-first-episode-of-psychosis","fullItemName":"Identifying someone at risk of a psychotic disorder or experiencing their first episode of psychosis"},{"id":"a8f36210-9cb6-590b-8e3d-7ddbc6d31e88","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f86ff69c-c33e-5b8c-affa-04759f25bf5a","fullItemName":"Management","slug":"management","subChapters":[{"id":"34c0807e-9463-536b-9ff4-c3537046a6ba","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"},{"id":"468f8b6f-bc79-5ecd-b1c2-d7ff27721abe","slug":"managing-relapse","fullItemName":"Scenario: Managing relapse"},{"id":"30f16f24-0127-53b7-bd08-c679a189090b","slug":"the-routine-schizophrenia-or-psychosis-review","fullItemName":"Scenario: The routine schizophrenia or psychosis review"},{"id":"c20919b9-2e4c-5c56-b3cd-7fb432199a8b","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"a9fe56bb-7ae3-5523-b0e2-5b7da5aa8439","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f78f8497-f98b-5445-82fe-23a4ced38576","slug":"available-antipsychotics","fullItemName":"Available antipsychotics"},{"id":"05e42d64-ee5a-5c2b-8817-5fc77abb19ec","slug":"adverse-effects","fullItemName":"Adverse effects"},{"id":"25b3e7d5-bc3d-5749-9304-a717c1f4e386","slug":"interactions","fullItemName":"Interactions"},{"id":"ed339043-f5e2-5209-9ba0-cb06890e1050","slug":"monitoring","fullItemName":"Monitoring"}]},{"id":"7ae82132-000d-507c-b73d-542c43656041","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1bf0a6af-76cf-5f6b-b7fb-4c746ff0f413","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"49b46ed4-7209-5c01-b07f-54117f9ad3c0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a4647644-8726-5bfc-b471-6e157c3f10a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a31ae673-4520-58d5-95ee-db2395fb5238","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3beebe4c-a826-5b46-a8cd-a97fe8ec3b8b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"aaaadecf-036b-531f-a8bf-75fccd84219f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49078833-deae-54f3-ad89-562370e4d181","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a9fe56bb-7ae3-5523-b0e2-5b7da5aa8439","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}